Premium
Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex
Author(s) -
Szabo Bela,
Fritz Thomas,
Wedzony Krzysztof
Publication year - 2001
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0704237
Subject(s) - rilmenidine , moxonidine , guanabenz , imidazoline receptor , clonidine , chemistry , endocrinology , medicine , locus coeruleus , prazosin , idazoxan , sympatholytic , norepinephrine , pharmacology , agonist , blood pressure , receptor , central nervous system , dopamine , antagonist
The aim of the present study was to compare the effects of the centrally acting antihypertensive drugs rilmenidine, moxonidine, clonidine and guanabenz on sympathetic tone with their effects on noradrenaline release in the cerebral cortex. In particular, the hypothesis was tested that rilmenidine and moxonidine, due to their high affinity for sympatho‐inhibitory imidazoline I 1 receptors and low affinity for α 2 ‐adrenoceptors, lower sympathetic tone without causing an α 2 ‐adrenoceptor‐mediated inhibition of cerebrocortical noradrenaline release. In rats anaesthetized with urethane, blood pressure and heart rate were measured and the concentration of noradrenaline in arterial blood plasma was determined. The release of noradrenaline in the medial prefrontal cortex was estimated by microdialysis. Intravenous administration of rilmenidine (30, 100, 300 and 1000 μg kg −1 ), moxonidine (10, 30, 100 and 300 μg kg −1 ), clonidine (1, 3, 10 and 30 μg kg −1 ) and guanabenz (1, 3, 10 and 30 μg kg −1 ) led to dose‐dependent hypotension and bradycardia; the plasma noradrenaline concentration also decreased. After the two highest doses, all four drugs lowered noradrenaline release in the prefrontal cortex. At doses eliciting equal hypotensive and sympatho‐inhibitory responses, rilmenidine and moxonidine inhibited cerebral cortical noradrenaline release at least as much as clonidine and guanabenz. The results show that rilmenidine and moxonidine lower cerebrocortical noradrenaline release at doses similar to those which cause sympatho‐inhibition. This effect was probably due to an α 2 ‐adrenoceptor‐mediated inhibition of the firing of locus coeruleus neurons and, in addition, to presynaptic inhibition of noradrenaline release at the level of the axon terminals in the cortex. The results argue against the hypothesis that rilmenidine and moxonidine, due to their selectivity for sympatho‐inhibitory I 1 imidazoline receptors, do not suppress noradrenergic neurons in the central nervous system.British Journal of Pharmacology (2001) 134 , 295–304; doi: 10.1038/sj.bjp.0704237